47 Hulfish Street
Princeton, NJ 08542
United States
609 662 2000
https://amicusrx.com
Settore/i:
Settore:
Impiegati a tempo pieno: 517
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Bradley L. Campbell M.B.A. | CEO, President & Director | 1,44M | 1,31M | 1976 |
Mr. Simon Nicolas Reade Harford | Chief Financial Officer | 573,06k | N/D | 1960 |
Ms. Ellen S. Rosenberg | Chief Legal Officer & Corporate Secretary | 896,29k | 309,81k | 1964 |
Mr. David M. Clark | Chief People Officer | 849,24k | N/D | 1976 |
Dr. Jeffrey P. Castelli Ph.D. | Chief Development Officer | 855,86k | N/D | 1972 |
Ms. Samantha Prout | Chief Accounting Officer & Controller | N/D | N/D | 1978 |
Dr. Jill Weimer Ph.D. | Chief Science Officer | N/D | N/D | N/D |
Andrew Faughnan | Senior Director of Investor Relations | N/D | N/D | N/D |
Mr. Patrik S. Florencio Esq. | Global Chief Compliance & Risk Officer | N/D | N/D | N/D |
Ms. Diana Moore | Head of Global Corporate Communications | N/D | N/D | N/D |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
L'ISS Governance QualityScore di Amicus Therapeutics, Inc. al 29 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 5; diritti degli azionisti: 7; retribuzione: 5.